Meeting
2015 ASCO Annual Meeting
Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: A randomized phase III study (GASTRIPEC).
Authors
Beate Rau
Charite Campus Mitte University of Berlin, Berlin, Germany
Beate Rau , Markus Loeffler , Horst-Guenther Rau , Udo Sulkowski , Jan Kuhlmann , Arved Weimann , Tobias Keck , Martin Angele , Stefan A. Topp , Alfred Koenigsrainer , Evelyn Kuhnt , Albrecht Kretzschmar , Wolfram Trudo Knoefel , Peter C. Thuss-Patience
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02158988
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS4132)
DOI
10.1200/jco.2015.33.15_suppl.tps4132
Abstract #
TPS4132
Poster Bd #
243b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.
First Author: Lin Shen
Poster
2020 Gastrointestinal Cancers Symposium
KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.
First Author: Hyun Cheol Chung
Poster
2019 ASCO Annual Meeting
KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.
First Author: Yelena Yuriy Janjigian
Poster
2018 Gastrointestinal Cancers Symposium
Patterns of chemotherapy (CT) use in a U.S.-wide cohort of patients (pts) with metastatic gastric cancer (MGC).
First Author: Thomas Adam Abrams